Efficacy and Tolerability of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency at a Hospital Outpatient Clinic: A Retrospective Cohort Study of Real-World Clinical Practice

Table 1

Demographic and clinical characteristics of the study population.

Characteristic	Patients; (N = 459)
Age (years), mean (SD)	58.6 (17.5)
Elderly > 65 years, n (%)	187 (40.7)
Male, n (%)	101 (22.0)
Anemia, n (%)	378 (82.4)
Iron deficiency, n (%)	450 (98.0)
Iron deficiency anemia, n (%)	373 (81.3)
Iron deficiency without anemia, n (%)	77 (16.8)
Cumulative FCM treatment dose, n (%)
500 mg	122 (26.6)
501–1000 mg	290 (63.2)
1001–3000 mg	47 (10.2)
Diagnosis per ICD-10 high level category, n (%)
Diseases of the digestive system	199 (43.4)
Diseases of the genitourinary system	121 (26.4)
Neoplasms	47 (10.2)
Diseases of the circulatory system	38 (8.3)
Other diseases	54 (11.8)

FCM: ferric carboxymaltose; ICD-10: International Classification of Diseases 10th Revision.